Trials: Moderate to Severe Chronic Plaque Psoriasis

Phase 3 N=159 A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)

Psoriasis

Primary: Number of Participants Who Achieve a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI) Score — 111; 111 Participants

Merck Sharp & Dohme LLC Results Dec 2010 1.3% serious AE View details

Phase 4 N=124 Moderate to Severe Plaque Psoriasis With Scalp Involvement

Psoriasis

Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001

Amgen Results Nov 2013 2.5% serious AE View details

Phase 3 N=443 MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Psoriasis · Plaque Type Psoriasis · Moderate to Severe Plaque Psoriasis

Primary: Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 16 — 89.7; 91.6 Percentage of Participants

Fresenius Kabi SwissBioSim GmbH Results Feb 2019 3.9% serious AE View details

Phase 3 N=120 Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

Psoriasis

Primary: Clinical Success — 18; 3 participants — p=0.0003

Sun Pharmaceutical Industries, Inc. Results Aug 2014 0.0% serious AE View details

Phase 4 N=29 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

Plaque Psoriasis

Primary: Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36 — 4; 2 participants

Psoriasis Treatment Center of Central New Jersey Results Jan 2019 4.4% serious AE View details

Phase 2 N=176 Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy

Chronic Plaque Psoriasis

Primary: Achievement of Psoriasis Activity and Severity Index (PASI75) Response at Week 12 — 6.8; 74.6; 82.8 percentage of subjects — p=<0.001

UCB Pharma Results May 2019 4.6% serious AE View details

Phase 1 N=29 A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants

Psoriasis

Primary: Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 — 5; 0…

GlaxoSmithKline Results Mar 2024 3.5% serious AE View details

Phase 4 N=39 Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

Psoriasis

Primary: Number of Patients With Physician's Global Assessment (sPGA) Score 0 or 1 — 24 Participants

Icahn School of Medicine at Mount Sinai Results Jul 2019 0.0% serious AE View details

Phase 3 N=303 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Psoriasis

Primary: Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline — 13.7…

Amgen Results Sep 2019 2.0% serious AE View details

Phase 2 N=42 A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 13; 7; 20; 11 Participants

Amgen Results Sep 2018 2.4% serious AE View details

Phase 2 N=255 A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

Plaque Psoriasis

Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16 — 9.3; 37.2; 58.1…

Janssen Research & Development, LLC Results Dec 2025 1.2% serious AE View details

Phase 2 N=152 Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis · Psoriasis · Skin Diseases

Primary: Percentage of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) at End-of-treatment (EOT) — 11.8; 22.0; 7.8 %…

Akros Pharma Inc. Results Aug 2021 2.7% serious AE View details

Phase 2 N=267 Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Psoriasis

Primary: The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85…

Bristol-Myers Squibb Results Nov 2020 1.5% serious AE View details

Phase 2 N=92 A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis

Psoriasis Vulgaris · Plaque Psoriasis

Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement — 4; 1; 0 Participants

PRCL Research Inc. Results Mar 2020 1.1% serious AE View details

Phase 2 N=259 Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 5.8; 18.0; 44.2…

Takeda Results Sep 2023 0.4% serious AE View details

Phase 3 N=1,647 Plaque Psoriasis Efficacy and Safety With Secukinumab

Plaque Psoriasis

Primary: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24 — 552; 496 Participants — p=0.1499

Novartis Pharmaceuticals Results May 2019 4.1% serious AE View details

Phase 2 N=132 Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Primary: Percentage of Participants Achieving Greater Than or Equal to (>=) 75% Reduction From Baseline in Psoriasis Area Severity Index (PASI) Score (PASI-75) at Week 16 — 58.3…

Meiji Pharma USA Inc. Results Jun 2024 1.5% serious AE View details

Phase 3 N=1,101 A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

Primary: Percentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12 — 47.11; 68.18; 66.27; 14.95 percentage of…

Pfizer Results May 2014 1.9% serious AE View details

Phase 4 N=352 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis

Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…

AbbVie Results Apr 2024 2.5% serious AE View details

Phase 4 N=38 A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)

Psoriasis

Primary: Psoriasis Area and Severity Index (PASI) 75 Response Rate at Week 10 — 71 Percentage of participants

Merck Sharp & Dohme LLC Results Feb 2011 18.4% serious AE View details

Phase 4 N=20 Topical Psoriasis Study for Patients Receiving Biologic Therapy

Psoriasis

Primary: Psoriasis Severity — 4.25 units on a scale

Psoriasis Treatment Center of Central New Jersey Results May 2018 0.0% serious AE View details

Phase 3 N=1,468 Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Primary: Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R — 76.5 percentage of participants

Abbott Results Nov 2010 12.9% serious AE View details

Phase 2 N=197 Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Primary: Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 — 25.00; 40.82; 66.67; 2.00 percentage of…

Pfizer Results Dec 2012 1.5% serious AE View details

Phase 3 N=595 Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

Psoriasis

Primary: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase — 4.1; 21.6 Percentage of…

Amgen Results May 2021 1.5% serious AE View details

Phase 3 N=202 Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

Psoriasis

Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 24 — 89.52; 33.68 Percentage of participants — p=<.0001

Novartis Pharmaceuticals Results Oct 2017 4.0% serious AE View details

Phase 2 N=33 An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

Psoriasis

Primary: The Mean Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI). — -25.08; -12.63 percent change — p=0.2205

Lycera Corp. Results Apr 2019 0.0% serious AE View details

Phase 3 N=43 Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

Plaque-type Psoriasis

Primary: Percentage of Participants (Who Achieved a Partial Response Defined as ≥ 50% But < 75% Improvement in Psoriasis Area and Severity Index (PASI) After 12 Weeks of…

Novartis Pharmaceuticals Results Mar 2015 1.1% serious AE View details

Phase 2 N=71 CP-690-550 Ointment For Chronic Plaque Psoriasis

Psoriasis

Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — -53.97; -41.01; -24.26; -17.24 percent change

Pfizer Results Jan 2021 0.0% serious AE View details

Phase 2 N=22 A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)

Psoriasis

Primary: Psoriasis Area and Severity Index 75 (PASI75) Response at Week 10 — 16 participants

Merck Sharp & Dohme LLC Results Mar 2010 0.0% serious AE View details

Phase 2 N=263 To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

Primary: Proportion of Subjects With at Least 75% Improvement in PASI (PASI 75) — 14.0; 28.3; 23.0; 16.7 percentage of subjects — p=0.1011

Sun Pharmaceutical Industries Limited Results Jan 2026 0.7% serious AE View details

Clinical Trial Search

Phase 3 N=159 A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)

Phase 4 N=124 Moderate to Severe Plaque Psoriasis With Scalp Involvement

Phase 3 N=443 MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Phase 3 N=120 Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

Phase 4 N=29 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

Phase 2 N=176 Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy

Phase 1 N=29 A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants

Phase 4 N=39 Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

Phase 3 N=303 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Phase 2 N=42 A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Phase 2 N=255 A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

Phase 2 N=152 Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

Phase 2 N=267 Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Phase 2 N=92 A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis

Phase 2 N=259 Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Phase 3 N=1,647 Plaque Psoriasis Efficacy and Safety With Secukinumab

Phase 2 N=132 Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

Phase 3 N=1,101 A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Phase 4 N=352 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Phase 4 N=38 A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)

Phase 4 N=20 Topical Psoriasis Study for Patients Receiving Biologic Therapy

Phase 3 N=1,468 Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2 N=197 Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 3 N=595 Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

Phase 3 N=202 Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

Phase 2 N=33 An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

Phase 3 N=43 Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

Phase 2 N=71 CP-690-550 Ointment For Chronic Plaque Psoriasis

Phase 2 N=22 A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)

Phase 2 N=263 To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis